# Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma

> **NCT04077983** · PHASE2 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Cholangiocarcinoma, Intrahepatic

## Interventions

- **DRUG:** combined therapy using nab-paclitaxel and gemcitabine chemotherapy

## Key facts

- **NCT ID:** NCT04077983
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-01
- **Primary completion:** 2020-09-01
- **Final completion:** 2022-09-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2019-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04077983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04077983, "Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04077983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*